From October 24th to 26th, the third quarter summary meeting of Huibang Biotech was successfully held in the company. Mr. Wang Zhongliang, chairman of the company, and sales elites from all over the country gathered together to summarize experience, share success, and communicate and improve.
- Ceremony for the appointment of Mr. Fang Zhaohui as Chief Scientist of Huibang National TCM Diagnosis and Treatment System -
- Professor Zhang Yan's recognition and support for Huibang Biotechnology -
(Please listen to the audio in the WeChat public account)
1. What is "appropriate technology"?
2. If municipal or county-level hospitals choose this appropriate technology, what is the significance for hospitals, departments and individual doctors?
3. When the premature rupture of membranes project enters the hospital, is it best to put it in the obstetrics and gynecology department or the laboratory department? How to fight for it?
4. During the clinical use of the premature rupture of membranes project, is the test result consistent with the patient's diagnosis? Has it withstood the clinical test?
- Professor Zhao Weidong delivered a speech to Huibang Biotechnology -
(Please watch the video in the WeChat public account)
Huibang Biotechnology is a national high-tech enterprise integrating R&D, production and sales. Over the years, relying on the geographical advantages of the local high-tech development zone in Hefei, the talent advantages of the Beijing expert technical team, and the advantages of raw materials such as the monoclonal antibody center established by itself, Huibang Biotechnology has established a certain leading position in the industry. As an in vitro diagnostic reagent company that produces key raw materials in the province, Huibang Biotech has developed and prepared various key raw materials in recent years, which changed the dilemma that key raw materials must be imported and formed an industrial chain development. Independent innovation products replace imported products, reduce medical costs, break the monopoly of foreign giants, benefit the people, and truly move from "Made in China" to "Created in China".
The "diabetic nephropathy detection" technology exclusively developed by Huibang Biotech has filled the gap at home and abroad. At the same time, haptoglobin is undergoing multi-center research in order to reach an expert consensus and write an industry diagnosis and treatment guideline. It is the first company in the world to realize the industrialization of anti-human haptoglobin monoclonal antibody products. The dual quantitative detection of premature birth and premature rupture of pregnant women and the "four items of child protection" detection of child health care are the first in China, and Huibang Biotech's other research projects are leading the industry. In terms of the innovation and leadership of scientific and technological research and development projects, Huibang Biotech has always been at the forefront of the industry.
In the future, Huibang Biotechnology will continue to uphold the belief of "helping the world with the heart, benefiting the people and rejuvenating the country", continue to explore, dig deep, and innovate the IVD industry, consolidate the foundation of benefiting the country, and pursue technological heights. At the same time, the deployment of home testing projects, relying on the Internet +, allows ordinary people to experience the convenience brought by modern medicine without leaving home.
(For more details, please pay attention to the WeChat public account)
